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Suboptimal Antituberculosis Drug Concentrations
and Outcomes in Small and HIV-Coinfected
Children in India: Recommendations for Dose
Modifications
Benjamin Guiastrennec1, Geetha Ramachandran2, Mats O. Karlsson1, A.K. Hemanth Kumar2,
Perumal Kannabiran Bhavani2, N. Poorana Gangadevi2, Soumya Swaminathan2, Amita Gupta3,
Kelly E. Dooley3 and Radojka M. Savic4
This work aimed to evaluate the once-daily antituberculosis treatment as recommended by the new Indian pediatric guide-
lines. Isoniazid, rifampin, and pyrazinamide concentration–time profiles and treatment outcome were obtained from 161
Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines.
The exposure–response relationships were established using a population pharmacokinetic-pharmacodynamic approach.
Rifampin exposure was identified as the unique predictor of treatment outcome. Consequently, children with low body
weight (4–7 kg) and/or HIV infection, who displayed the lowest rifampin exposure, were associated with the highest proba-
bility of unfavorable treatment (therapy failure, death) outcome (Punfavorable). Model-based simulation of optimized
(Punfavorable 5%) rifampin once-daily doses were suggested per treatment weight band and HIV coinfection status (33%
and 190% dose increase, respectively, from the new Indian guidelines). The established dose-exposure–response relation-
ship could be pivotal in the development of future pediatric tuberculosis treatment guidelines.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 India recently updated its national tuberculosis treatment
guidelines and is now moving toward a once-daily dosing regi-
men. The optimal doses of first-line drugs for all children, in
India or elsewhere, has not been firmly established.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What are the subpopulations at risk of unfavorable treat-
ment outcomes (therapy failure, death), and what modifications
can be made to the new once-daily Indian pediatric tuberculosis
treatment guidelines to reduce this risk in these subgroups?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Low rifampin exposures were linked to an increased proba-
bility of unfavorable treatment outcome. Rifampin exposure
was the lowest in children with low body weight or HIV
coinfection.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Clinical practice in India is evolving and this work provides
vital information to inform dosing guidelines of the future.
More specifically, our simulations suggest that higher antituber-
culosis drug dose levels in Indian children, especially those with
low body weight or HIV coinfection, can potentially prevent
treatment failure or death.
The World Health Organization (WHO) estimates that among
the 10.4 million new incident cases of tuberculosis (TB) in 2015,
1 million occurred in children.1 India has the highest TB burden
in the world, accounting for 27% of total incident cases.1 TB risk
in India is increased with HIV coinfection, young age, malnutri-
tion, and other comorbidities that can intensify disease severity
and lower the overall exposure of anti-TB drugs.2,3
The introduction of India’s Revised National TB Control Pro-
gramme (RNTCP) has reduced the incidence of TB by providing
free diagnosis and treatment, and by using the Directly Observed
Treatment Short-course (DOTS) strategy.4 Studies demonstrated
that the previous thrice-weekly dosing of first-line anti-TB in
RNTCP guidelines could lead to suboptimal anti-TB drug con-
centrations in both adults and children.5,6 Consequently, the
RNTCP pediatric guidelines were revised in 2012, refining the
dosing weight bands and increasing the rifampin (RIF) dose from
10 to 15mg/kg, although still recommending thrice-weekly dos-
ing.7 In 2016, new RNTCP guidelines were issued to initiate the
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transition toward a once-daily dosing regimen in an effort to
align with WHO recommendations.8,9 These new guidelines are
currently being evaluated via pilot studies and once-daily dosing
is anticipated to be rolled out throughout India by the end of
2017.9 Herein, the pre-2012 and 2016 guidelines will be respec-
tively being referred to as “previous” and “new” RNTCP
guidelines.
Few studies have attempted to link the pharmacokinetic (PK)
of anti-TB drug to treatment outcomes in children,10–13 owing
to challenges in the assessment of microbiologic treatment
response, and this has resulted in a lack of exposure–response (or
pharmacodynamic (PD)) data to inform dosing recommenda-
tions for children.14,15 Population PK-PD modeling can be used
to relate the time-course of drug exposure to drug effects (e.g.,
clinical outcome) while investigating sources of variability among
individuals and to evaluate alternative dosing regimens through
simulations.16,17
Using a population PK-PD approach, we evaluated the impact
of individual-level factors associated with an increased probability
of unfavorable treatment (therapy failure, death) outcome
(Punfavorable) in children with drug-sensitive TB treated according
to the previous thrice-weekly Indian RNTCP pediatric guide-
lines. We then evaluated the new once-daily Indian dosing rec-




Model development was performed on the data from 161 Indian
children with TB monoinfection or TB-HIV coinfection pooled
from two noninterventional studies11,12; population characteris-
tics are summarized in Table 1. In total, 805 plasma concentra-
tions were collected for isoniazid (INH), 794 for rifampin (RIF),
and 720 for pyrazinamide (PZA). Samples below the detection
limit (INH: 148, RIF: 174, PZA: 75) were excluded from the
analysis. Trough concentrations (24–72 h post previous dose)
represented most of the excluded samples (INH: 125, RIF: 105,
PZA: 67). Time concentration profiles are presented in Figure 1.
Among the tested candidate models, a two-compartment
model best described INH disposition, whereas one-
compartment models adequately described RIF and PZA data.
Other aspects of the PK models were similar for all three drugs as
highlighted hereafter. Absorption delays were described by chains
of transit compartments, where significant between subject vari-
ability (INH 49.8%, RIF 64.4%, PZA 42.5% coefficient of varia-
tion (CV)) was identified in the mean transit time. Substantial
between subject variability was also identified in apparent clearan-
ces (INH 74.2%, RIF 45.4%, PZA 37.4% CV) and volumes
(INH 44.9%, RIF 37.3%, PZA 34.4% CV) parameters; both
parameters were highly correlated (INH 86.9%, RIF 78.8%, PZA
51.7%). Residual error was best described by a combined model
for INH and additive models for RIF and PZA. Equations
and parameter estimates for the selected models are shown in
Supplementary Material S1.
Throughout the search for individual-level factors influencing
the PK, a pronounced nonlinear relationship described by an
allometric-type function was identified between total body weight
and relative bioavailability for all three drugs (Figure 2), sugges-
ting that the smallest children will have the lowest relative bio-
availability. Additionally, children with TB-HIV coinfection had
a substantial increase in RIF clearance (131.6%), decrease in RIF
relative bioavailability (–41.5%), and decrease in INH relative
bioavailability (–19.5%) estimates in comparison to HIV-
uninfected children, leading to further substantial decrease in
RIF and INH plasma levels and total exposures (Figure 2).
Furthermore, a considerable increase was observed in RIF
between-subject variability in clearance (174.0%) and volume of
distribution (1106%) in TB-HIV coinfected children, leading to
large variations in drug exposure.
The selected INH, RIF, and PZA models were evaluated and
shown to accurately predict drug exposure and describe the data
across the different RNTCP weight bands (Supplementary
Material S2).
Treatment outcomes analysis
Among the 161 children included in the study, treatment out-
come was favorable for 109 (68%), unfavorable for 33 (20%),
and unknown for 19 (12%) (Table 1). For children with
unknown outcome, no assumptions could be made regarding the
reason behind the dropout, and these subjects were excluded
from the analysis.
A covariate search was conducted to evaluate the effect of
individual-level factors on the treatment outcome. Throughout
this search, effects of subjects’ characteristics and INH, RIF, and
PZA total weekly drug exposures at steady state were tested. Area
under the concentration–time curves (AUC) was preferred over
peak concentration as a marker of drug exposure; both metrics
were, however, highly correlated (INH: 78%, RIF: 91% and
PZA: 77%). Among all tested covariates, RIF exposure (9.81–
231 lg.h/mL range) was the only independent predictor (P <
0.01) of Punfavorable. No statistically significant effect of INH
(P5 0.74) or PZA (P5 0.81) exposures could be detected on
Punfavorable within the ranges seen in this study (INH: 3.89–
346 lg.h/mL and PZA: 351–2780 lg.h/mL). In addition to
their effects on drug PK, HIV status and body weight were also
tested on Punfavorable. There was a trend towards HIV status hav-
ing an independent effect on outcomes (P5 0.075), but weight
had no impact on outcomes independent of its effect on RIF PK
(P5 0.91). Owing to differences in weekly RIF exposure, the
model-predicted odds ratio was 2.27 (95% confidence interval:
1.27–4.05) for TB-HIV coinfection (median AUC: 36.8 lg.h/
mL) in reference to TB monoinfection (median AUC:
93.6 lg.h/mL) and 1.68 (95% confidence interval: 1.16–2.41)
for children in the 6–10 kg weight band (median AUC:
60.7 lg.h/mL) in reference to the 26–30 kg weight band (median
AUC: 96.5 lg.h/mL).
A model-derived weekly RIF exposure (185 lg.h/mL) to
achieve a target Punfavorable of 5% or less was used for dose regi-
men evaluation. The relationship between RIF exposure and
Punfavorable is illustrated in Figure 3. Equations, parameter esti-
mates, and predictive performances of the selected model are pro-
vided in Supplementary Material S3.
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RNTCP dosing regimen evaluation
The simulation of treatment outcome under previous and new
RNTCP dosing regimens (Figure 4, Table 2) revealed an
increased Punfavorable for children with low body weight (6–10 kg
for previous and 4–7 kg for new RNTCP guidelines) due to sub-
optimal mg/kg rifampin dose in this group or TB-HIV coinfec-
tion. Among those with HIV-TB, the median Punfavorable was as
high as 35%. Punfavorable, however, is expected to be reasonable
(5%) in most children with TB monoinfection under the new
once-daily RNTCP dosing regimen.
Model-based optimized once-daily doses of RIF (i.e., based on
the target RIF exposure to achieve Punfavorable 5%) were calcu-
lated for children based on their body weight and HIV status.
These doses are summarized in Table 3 and organized by the
new RNTCP treatment weight bands and by TB-HIV coinfec-
tion status. The predicted optimal doses were increased for chil-
dren with low body weight (4–7 kg) and especially for TB-HIV
coinfected children, with doses up to 43.4mg/kg. However, for
children with TB monoinfection or TB-HIV coinfection with a
body weight greater than 25 kg, the model predicted that low
rates of Punfavorable, could be achieved, even with once-daily doses
as low as 5.2mg/kg.
DISCUSSION
The study presented herein extends the work from Swaminathan
et al.,13 who exposed a link between low antituberculosis expo-
sure and unfavorable treatment outcome in Indian children
treated according to the previous RNTCP thrice-weekly dosing
recommendations. This study was tailored to evaluate the new
Indian dosing recommendations, identify subgroups for whom
the new recommendations will result in suboptimal drug expo-
sures, and use modeling to suggest dosing revisions to consider. A
population PK-PD modeling approach was selected to enable the
establishment of the dose-exposure–response relationships, the
identification of subgroups of subjects “at risk,” and the simula-
tions of alternate dosing regimens.
Our main finding was that the previously recommended thrice-
weekly RNTCP dosing along with constant mg/kg dosing across
all pediatric weight bands resulted in an increased Punfavorable in
children with low body weight (6–10 kg) and/or TB-HIV coin-
fection due to suboptimal weekly RIF exposure. Furthermore,
model-based simulations indicated that suboptimal RIF concen-
trations could also be expected in these subpopulations for chil-
dren treated according to the new once-daily RNTCP dosing
recommendations.
Table 1 Population characteristics and treatment outcomes
TB monoinfection study TB-HIV coinfection study P valuea Total
Covariatec
Number of participants 84 77 NA 161
Sex (male/female) 41/43 50/27 0.040 91/70
Age (years) 8 (5–11) 9 (7–11) 0.008 8 (6–11)
Weight (kg) 17.8 (12.9–22.8) 17.0 (14.2–22.4) 0.734 17.5 (13.9–22.5)
BMI (kg/m2) 14.1 (12.7–15.2) 14.4 (13.4–15.5) 0.240 14.2 (13.3–15.3)
INH acetylator (slow/rapid) 57/27 52/25 0.967 109/52
ART usage 0 45 NA 45
CD4 cell count (%) — 11.0 (5.0–19.5) NA —
Z-scoresb
HAZ 21.2 (22.1 to20.29) 23.0 (24.1 to22.0) <0.001 22.0 (23.2 to20.93)
WAZ 21.8 (22.4 to21.1) 22.7 (23.4 to21.9) <0.001 22.2 (22.9 to21.4)
Tuberculosis type <0.001
Pulmonary 19 49 68
Extra pulmonary 63 28 91
Both 2 0 2
Treatment outcome 0.443
Favorable 55 54 109
Unfavorable 15 18 33
Unknown 14 5 19
ART, antiretroviral treatment; BMI, body mass index; HAZ, height for age Z-score; HIV, human immunodeficiency virus; INH, isoniazid; NA: not applicable; TB, tuberculosis;
WAZ, weight for age Z-score.
aStatistical testing performed using a Mann–Whitney U test at 5% level of significance. bZ-scores calculated using the EPI-INFO 2002 software package (v. 3.4.3; Centers
for Disease Control and Prevention, Atlanta, GA). cn or Median (Interquartile Range).
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 104 NUMBER 4 | October 2018 735
 ARTICLE
Interestingly, published INH, RIF, and PZA population PK
models in TB infected South African children did not adequately
fit the data from Indian children.18 Overall, published models in
South African children indicated higher apparent clearance,
shorter absorption delays, and smaller apparent volume for all
three drugs compared to the Indian children studied herein. The
origin of these differences (i.e., analytical, formulation, genetic or
nutritional factors, magnitude of autoinduction) could not be
investigated with the current study design.2 Herein, relative bio-
availability was found to be nonlinearly correlated with total
body weight resulting in lower drug exposures in children with
low body weight. Given the dosing protocol, body weight, how-
ever, was highly correlated with age and dose. Thus, beyond the
effect of body size, this finding may partly be explained by differ-
ences in tablet formulation used for the 6–10 kg weight
band.19,20 Furthermore, as similar trends were observed for INH,
RIF, and PZA, other factors such as malabsorption due to disease
severity or malnutrition could also have contributed to the
effect.2,15,21 Whether or not TB-HIV coinfection impacts the
PK of anti-TB drugs is debated.5,18 Herein, HIV status had a
pronounced and clinically relevant impact on TB drug pharma-
cokinetics observed as lower INH (–19.5%) and RIF (–41.5%)
relative bioavailability, higher RIF clearance (131.6%), and
higher between-subject variability on clearance (174%) and vol-
ume of distribution (1106%). These effects were associated with
TB-HIV coinfection rather than the use of antiretroviral treat-
ment (ART). Children in the TB-HIV coinfection study were
more severely affected by malnutrition (median height for age Z-
score (HAZ)5 –3.0 and weight for age Z-score (WAZ)5 –2.7)
than children with TB monoinfection (median HAZ5 –1.2 and
WAZ5 –1.8). Thus, the observed effects of TB-HIV coinfection
on apparent clearance and relative bioavailability were likely due
to a complex combination of factors including: drug–drug inter-
actions, malabsorption, and malnutrition, which are not indepen-
dently distinguishable with the current study design.22–24
Treatment outcome in Indian children has herein been linked
to the PK of INH, RIF, and PZA through a population PK-PD
approach. The in vitro activities of INH, RIF, and PZA have
been shown to correlate well with both AUC and peak concen-
tration.25,26 In order to facilitate the translation from thrice-
weekly to daily dosing, AUC was selected as a marker of drug
exposure over peak concentration. AUC and peak concentrations
were, however, highly correlated for all three drugs (INH 78%,
RIF 91%, and PZA 77%). Weekly RIF exposure at steady state
was the only independent predictor of treatment outcomes. This
should not be interpreted as RIF being the only active drug in
TB treatment, but rather that despite similar exposure trends of
the INH and PZA across individuals (e.g., low body weight), RIF
was likely the most severely underdosed anti-TB drug. Even
though no additional covariate effect was supported by the data
on the treatment outcomes, body weight and HIV coinfection
substantially affected Punfavorable through their impact on RIF
exposure. Despite differences in the studied populations, dosing
regimen, and methodology, others have also reported an increased
rate of low RIF exposure or unfavorable treatment outcome in
adults and children with low body weight or with TB-HIV
coinfection.22,24,27–30
The treatment outcome under thrice-weekly vs. once-daily dos-
ing in children has been the topic of a long debate, leading to
conflicting conclusions.31 The population PK-PD approach used
in this analysis allowed us to predict treatment outcomes under
different scenarios while integrating the effect of covariates and
Figure 1 Individual time–concentration profiles for isoniazid (left panel), rifampin (middle panel), and pyrazinamide (right panel). For each drug, the mean
(thick line) and standard errors (error bars) are provided for subjects with tuberculosis (TB) monoinfection and TB-HIV coinfection (colors). The horizontal
lines and numbers denote the commonly presumed target peak concentration for each drug.12 [Color figure can be viewed at cpt-journal.com]
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the variability in PK parameters. The model-based simulations
showed a clear trend toward higher Punfavorable under previous
thrice-weekly dosing compared to new once-daily dosing
RNTCP recommendations.7,9 The new RNTCP guidelines,
similar to guidelines in other settings, still assumes similar mg/kg
dose levels across weight bands, disregarding maturation processes
occurring throughout childhood.32 Thus, under previous and
new RNTCP dosing recommendations, Punfavorable was at the
highest in the first (previous: 6–10 kg and new: 4–7 kg) weight
band due to a low RIF exposure when compared to the older
children. On the basis of the simulations, children with TB-HIV
coinfection treated with the new RNTCP-recommended doses
also displayed higher Punfavorable than children with TB monoin-
fection across all weight bands. Although no TB treatment guide-
lines currently recommend an increase of RIF doses for subjects
with TB-HIV coinfection, there is accumulating evidence that
higher RIF doses along with nutritional supplementation may
significantly improve outcomes in this population.5,22,24,33,34
Optimized RIF doses based on a target weekly exposure criteria
associated with a Punfavorable of 5% or less are herein proposed to
overcome poor treatment outcomes in some subgroups. This
work represents the first step in the definition of a target expo-
sure derived from pediatric data. Additional studies should be
conducted to refine this target or extend to additional endpoint
such as a target daily peak concentration. Moreover, the tolerabil-
ity of dose increases in children should be carefully evaluated in
appropriate clinical studies. Encouragingly, RIF has lately been
tested in adults at doses up to 35mg/kg without a significant
increase in the incidence of side effects, and children are generally
recognized to be more tolerant than adults to anti-TB treatment
at similar mg/kg.35–37
The present study has several limitations. First, the PK sam-
pling times at 0, 2, 4, 6, and 8 h postdose were not optimal for
Figure 2 Effect of total body weight on the weekly area under the concentration–time curve (AUCwk) (top row), apparent clearance (middle row), and the typi-
cal relative bioavailability (bottom row) of pyrazinamide (left column), isoniazid (middle column), and rifampin (right column) for children in the TB monoinfec-
tion study (solid lines) or in the TB-HIV coinfection study (dotted lines). AUCwk and clearance in South African children (light gray lines) were predicted
according to Zvada et al.18 For AUCwk calculation, once-daily doses of 35, 10, and 15 mg/kg were used for pyrazinamide, isoniazid, and rifampin, respec-
tively. For clarity reasons, age maturation was not accounted for in the calculation of the clearances. [Color figure can be viewed at cpt-journal.com]
Figure 3 Median (line) and 95% confidence interval (shaded area) of the
model simulated probability of unfavorable treatment outcome (Punfavorable)
as a function of the weekly rifampin exposure at steady state (AUCRIF_wk_ss).
The vertical line marks the defined target AUCRIF_wk_ss associated with Punfav-
orable of 5%. [Color figure can be viewed at cpt-journal.com]
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estimation of absorption-related parameters and required the use
of literature priors to support the estimation of the absorption
rate constant of INH, RIF, and PZA.18,36 The predictive per-
formances of the models were, however, carefully evaluated
(Supplementary Materials S2). Second, the developed model
may not be generalizable to other populations, as differences in
the apparent clearances and volume of distribution were observed
in our Indian cohort compared with South African children
(Figure 2), possibly due to poor nutritional status in our study
population.12,18 Third, TB-HIV coinfection was associated with
Figure 4 Predicted probability of unfavorable treatment outcome (Punfavorable) under previous (left panel), new (central panel), and optimized (right panel)
revised national TB control program (RNTCP) dosing recommendations. Rifampin weekly exposures at steady state were simulated (n51,000) for
children within the pediatric RNTCP weight range (i.e., 6–30 kg for previous and 4–39 kg for new and optimized dosing recommendations); Punfavorable
distributions were computed for each weight band, and TB-HIV coinfection status. [Color figure can be viewed at cpt-journal.com]
Table 2 Intensive phase pediatric dosing as recommended by the Revised National Tuberculosis Control Program (RNTCP)
Punfavorable
d
Weight band Isoniazid dose Rifampin dose Pyrazinamide dose Ethambutol dose TB monoinfection TB-HIV coinfection
kg mg (mg/kg)a mg (mg/kg)a mg (mg/kg)a mg (mg/kg)a median (CI95) median (CI95)
Previous thrice-weekly RNTCP recommendationsb 7
6–10 75 (9.4) 75 (9.4) 250 (31.3) 200 (25.0) 0.272 (0.196–0.330) 0.352 (0.261–0.395)
11–17 150 (10.7) 150 (10.7) 500 (35.7) 400 (28.6) 0.184 (0.104–0.251) 0.304 (0.202–0.367)
18–25 225 (10.5) 225 (10.5) 750 (34.9) 600 (27.9) 0.127 (0.0698–0.196) 0.268 (0.158–0.34)
26–30 300 (10.7) 300 (10.7) 1,000 (35.7) 800 (28.6) 0.092 (0.0304–0.177) 0.242 (0.0836–0.336)
New once-daily RNTCP recommendationsc 9
4–7 50 (9.1) 75 (13.6) 150 (27.3) 100 (18.2) 0.105 (0.0331–0.191) 0.241 (0.114–0.345)
8–11 100 (10.5) 150 (15.8) 300 (31.6) 200 (21.1) 0.034 (<0.01–0.0932) 0.154 (0.039–0.288)
12–15 150 (11.1) 225 (16.7) 450 (33.3) 300 (22.2) 0.0113 (<0.01–0.0519) 0.103 (0.0116–0.235)
16–24 200 (10.0) 300 (15.0) 600 (30.0) 400 (20.0) <0.01 (<0.01–0.0178) 0.0659 (0.0102–0.181)
25–29 225 (8.3) 375 (13.9) 850 (31.5) 575 (21.3) <0.01 (<0.01–0.0175) 0.0521 (<0.01–0.195)
30–39 250 (7.2) 450 (13.0) 1,100 (31.9) 750 (21.7) <0.01 (<0.01–<0.01) 0.0396 (<0.01–0.123)
aDoses in mg/kg reported for the average total body weight of each weight band. bDoses administered thrice-weekly using single drug formulation. cDoses administered
once-daily using fixed dose combination (FDC) tablets. dReported as median and the 95% confidence interval (CI95) around the simulated medians (n51,000). Simulations
performed using the developed population PK-PD model.
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important changes in the RIF exposure, although all subjects
with TB-HIV coinfection were recruited as part of one study11
and all subjects with TB monoinfection as part of another
study.12 This design could have possibly contributed to the mag-
nitude of the observed effect. Thus, caution should be used in the
interpretation of the differences between subjects with TB alone
vs. TB-HIV coinfection. Fourth, treatment outcome was mod-
eled as favorable in the case of treatment completion or cure and
unfavorable in the case of treatment failure or death. Therefore,
the treatment outcomes model could not distinguish between
death and treatment failure. This strategy, however, was selected
due to the relatively small incidence of deaths (nine cases) in the
studied population.11,12 Furthermore, children with missing out-
come (19 cases) had to be excluded from the treatment outcome
analysis. While the treatment outcome in these children could
not be inferred, having a treatment outcome missing was not
linked with any specific characteristics associated with either
favorable or unfavorable outcome, and thus were not expected to
impact the conclusions. Fifth, the predicted optimized doses did
not account for possible RIF PK nonlinearity in the extrapola-
tion to high dose levels.36 RIF is also known to induce its own
metabolism and this should be considered when shifting from
thrice-weekly to once-daily dosing and/or increasing dose levels.38
Given the design of the current study, development of an RIF
autoinduction model was not possible. Integration of the RIF
autoinduction model from Smythe et al. in the treatment out-
come suggested that the proposed optimized doses in Table 3
might need to be increased by 20% on average to accommodate
the expected autoinduction (data not shown).39 Since the effect
of maturation on RIF autoinduction has not properly been evalu-
ated in children, the proposed doses should be confirmed clini-
cally prior to their implementation.
In conclusion, the new Indian pediatric dosing recommenda-
tions could be evaluated through a population PK-PD approach
linking the anti-TB exposure to the probability of unfavorable
outcome. The main findings were an increased risk of poor treat-
ment outcomes in children with low body weight and with
TB-HIV coinfection under the previous thrice-weekly RNTCP
dosing regimen. While the new once-daily RNTCP dosing
regimen showed an overall improvement of predicted treatment
outcome, children with low body weight and TB-HIV coinfec-
tion are still expected to display higher than expected rates of
poor outcomes due to the use of constant mg/kg doses across
weight bands. Optimized RIF doses based on a weekly RIF target
exposure are provided. Clinical practice in India is rapidly evolv-
ing and the work presented herein may represent a cornerstone




Data were obtained from two noninterventional studies in treatment-
naive Indian children aged 1–15 years, diagnosed with drug-sensitive TB
monoinfection (n5 84) or TB-HIV coinfection (n5 77).11,12 Clinical
examination and phenotypic INH acetylator status determination were
performed upon recruitment (Table 1). Children were recruited from
six study sites located in India, including: Agra, Bengaluru, Chennai, and
Madurai. Studies were approved by the Institutional Ethics Committees
of all study sites.11,12 Subjects’ parent/guardian provided written
informed consent; children aged 7 or older provided assent.
Study design
Children received a thrice-weekly course of anti-TB treatment according
to previous RNTCP guidelines for 6 months.7 Treatment was provided
in patient-wise boxes available in four different weight bands (Table 2).
Children eligible for ART were treated according to the National AIDS
Control Organization guidelines.40 At least two weeks after treatment
initiation, PK profiles of INH, RIF, and PZA were evaluated and
anthropometrics measurements were recorded. Doses were administered
by the study team after an overnight fast. Children continued anti-TB
treatment and ART whenever required according to guideline recom-
mendations. At the end of the study, TB treatment outcomes were
reported as unfavorable (i.e., treatment failure or death), favorable (i.e.,
treatment completion or cure) or unknown (i.e., lost during follow-
up).11,12
Data collection
On the PK study day, 2-mL blood samples were drawn at trough and 2,
4, 6, and 8 h postdose. INH, RIF, and PZA concentrations were deter-
mined by validated high-performance liquid chromatography meth-
ods.41,42 Assays were linear within the following ranges of plasma
concentration: 0.25–10.0 lg/mL for INH, 0.25–15.0 lg/mL for RIF
and 1.25–50.0 lg/mL for PZA. Between- and within-run variation were
Table 3 Optimized once-daily dosing regimen of rifampina




mg (mg/kg) median (CI95) mg (mg/kg) median (CI95)
4–7 109 (19.9) 0.0535 (0.0107–0.129) 239 (43.4) 0.0606 (<0.01–0.202)
8–11 126 (13.3) 0.0554 (0.0129–0.126) 275 (28.9) 0.0591 (<0.01–0.196)
12–15 139 (10.3) 0.0506 (0.0107–0.124) 311 (23.0) 0.057 (<0.01–0.18)
16–24 154 (7.7) 0.048 (0.0162–0.101) 346 (17.3) 0.0464 (<0.01–0.149)
25–29 166 (6.2) 0.0484 (0.0106–0.124) 383 (14.2) 0.0492 (<0.01–0.188)
30–39 180 (5.2) 0.0478 (0.0173–0.0966) 404 (11.7) 0.0509 (<0.01-0.142)
aOptimized doses given for single drug formulations. bDoses in mg/kg calculated using the average total body weight of each weight band. cReported as median and the
95% confidence interval (CI95) around the simulated medians (n51,000). Simulations performed using the developed population PK-PD model.
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below 10% for all drugs. Lower limits of quantification for INH, RIF,
and PZA were 0.25 lg/mL, 0.25 lg/mL, and 1.25 lg/mL, respectively;
lower limits of detection were 0.1 lg/mL, 0.1 lg/mL, and 0.5 lg/mL,
respectively. Average recovery from plasma were 104%, 104%, and 102%,
respectively. Additional details regarding the analytical assays can be
found in prior publications.41,42
Drug concentrations analysis
The concentration–time profiles of INH, RIF and PZA were modeled
separately. For each drug, one- and two-compartment models with
linear/saturable elimination and constant/saturable relative bioavailabil-
ity were evaluated. Herein, the relative bioavailability was defined as the
difference of bioavailability of a given individual in relation to the typical
individual (i.e., 17.8 kg individual with TB monoinfection). Due to the
sparseness of the data during the absorption phase, estimation of first-
order oral absorption rate constants was supported by use of prior infor-
mation from published models for INH,18 RIF,36 and PZA.18 Delays in
drug absorption were tested using chains of transit compartments.18,43
Between-subject variability was investigated on structural model parame-
ters and was assumed to follow a log-normal distribution. Proportional,
additive, and combined (i.e., proportional and additive) error models
were evaluated to describe the residual unexplained variability (e.g., mea-
surement error).
Allometric scaling based on total body weight (normalized by the pop-
ulation median: 17.8 kg) was applied to apparent clearances and volumes
using exponents of 3=4 and 1, respectively. Age-related maturation param-
eters for INH and RIF clearances and RIF absorption delay were set to
literature values.18 The effects of rapid INH acetylator genotype were
implemented on clearance and the relative bioavailability based on prior
information.18,44 A covariate search was performed to identify the effect
of influential factors on drugs exposure. As part of this process, effects of
age, total body weight, dose, sex, nutritional status, TB-HIV coinfection,
and ART intake were investigated on apparent clearances, volumes, and
relative bioavailabilities. All covariate-parameter relationships were
sequentially tested using forward selection (P < 0.05) followed by back-
ward deletion steps (P  0.01) to account for multiple testing. The
effect of categorical covariates was implemented as fractional change in
the typical parameter value in relation to the reference (i.e., most com-
mon) category. Continuous covariates were first implemented using lin-
ear relationships; nonlinear relationships were tested for upon their
inclusion in the forward selection step.
Treatment outcomes analysis
The treatment outcome was reported as either favorable for cure (based
on bacteriological evidence) and therapy completion (based on clinical
evaluation) or unfavorable for therapy failure (based on clinical, microbi-
ologic, or radiographic failure) and death. Treatment outcome (favorable
vs. unfavorable) was modeled using a logistic regression model, where
Punfavorable was expressed as a function of predictors. Odds ratios were
calculated using the exponent of the estimated effect slope. Effects of
INH, RIF, and PZA drug exposures implemented as the total weekly
area under the concentration–time curve and subject characteristics were
tested as predictors through forward selection (P < 0.05) and backward
deletion steps (P  0.01).
Parameter estimation and model selection
Population PK-PD analyses were performed in NONMEM (v. 7.3; Icon
Development Solutions, Ellicott City, MD) and aided by functionalities
of the PsN toolkit (v. 4.5.2).45,46 PK data were fitted using a first-order
conditional estimation method with interaction. Parameter uncertainty
expressed as relative standard error (RSE) was obtained from the NON-
MEM sandwich estimator computed with an importance sampling step.
Model selection was guided by evaluation of goodness-of-fit plots, param-
eter estimates values, and comparison of the objective function values
(–2log likelihood) with a significance level of P < 0.05 (2-sided) for
nested models. Throughout their development, model predictions were
also evaluated with simulation-based diagnostics.47 Finally, the capacity
of the selected PK models to properly predict drug exposure was assessed
using performance predictive checks plots where the observed population
drug exposure median was compared to the distribution of 1,000 simu-
lated population medians of drug exposure.48
RNTCP dosing regimen evaluation
The selected PK-PD model was used to predict Punfavorable under previ-
ous and new RNTCP dosing regimens. Accordingly, drug exposures
were simulated 1,000 times for children within the RNTCP pediatric
weight range (i.e., 6–30 kg for previous and 4–39 kg for new dosing rec-
ommendations). Punfavorable were then individually computed and sum-
marized for previous and new RNTCP weight bands and for each
significant covariate of treatment outcomes. In line with WHO’s sug-
gested target efficacy for drug-sensitive TB, the drug exposure associated
with a target Punfavorable of 5% or less was used to compute the optimized
dose for each simulated subject.49 These optimized doses were then sum-
marized for each of the new RNTCP treatment weight bands.9
Additional Supporting Information may be found in the online version of
this article.
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